Answers are grounded in this paper and cite their sources.
PEOPLE, PLACES, AND THINGS Moving into February and Springtime, academic meetings start stacking up, especially in subspecialty areas. This month we feature a urologic oncology fellow’s comments on Genitourinary American Society of Clinical Oncology from Dr Zahalka from UT Southwestern. San Francisco played host to the 2025 Genitourinary American Society of Clinical Oncology conference. Although the Fog City was cold and rainy (Figure 1), the conference was anything but. Day 1 featured groundbreaking abstracts on metastatic prostate cancer. A common theme for treatment de-escalation emerged among talks. The keynote talk about artificial intelligence (AI) in cancer care highlighted advances in the field including emerging applications such as marking areas of concern for biopsy during endoscopies/colonoscopies in real time. Silicon Valley, the nation’s tech capital and home to many AI startups, was an apt location for this talk, especially with its numerous AI offerings including fully autonomous driverless ride share taxis (Figure 2). The latest and greatest in bladder cancer and upper tract treatment management was presented on Day 2. A session titled the ABCs of ADCs (antibody drug conjugates) highlighted the potential and the potent side effects of this emerging class of drugs. Biomarkers that predict treatment response/prognosis are included in a growing number of bladder cancer trials, and the value and limitations of urinary cell–free tumor DNA were discussed in the aptly titled session Panning for Gold (Figure 3). The rain stopped and sun emerged on the last day of the conference, in time for the kidney/penile/testis/urethral cancer sessions. New data reinforced old concepts that more is not necessarily better, with data showing that upfront combination of multiple treatment agents increased toxicity with diminishing therapeutic returns.Figure 1.: Places. The rainy streets of San Francisco. The city hosted another excellent multidisciplinary conference on genitourinary cancers and is cosponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.Figure 2.: Things. Artificial intelligence is a hot topic across medical fields, and a well-matched feature for Genitourinary American Society of Clinical Oncology meeting near the Silicon Valley tech hub—spotted on the streets an autonomous driverless ride share taxi.Figure 3.: People. A Genitourinary American Society of Clinical Oncology plenary session on liquid biopsy methods in oncology.To complement the science, the conference offered numerous networking opportunities including a lunch for trainees and early-career attendees with established faculty and cocktail hour to browse and chat with poster presenters about their work. After an exciting day of digesting the latest developments in the field began a night of happy hours, rep dinners, and a chance to catchup with colleagues old and new. The city’s diversity was on full display with the wide range of culinary options for all budgets, including a warm bowl of Ramen (Figure 4) to combat the dreary weather. The conference concluded and the clouds parted to showcase local events including the annual Lunar New Year parade and the National Baseketball Association Allstar game.Figure 4.: Things. A final meeting day culinary treat at a networking event for trainees and early career faculty.FEBRUARY 2025 JUOP ARTICLES Clinical Trials Hoffman et al1 presented a phase 1 clinical safety trial of cryotherapy for superficial, low-grade bladder cancer. They treated 13 patients with 24 lesions. A postprocedure confirmatory biopsy was negative in 83%, and they discuss learning curve and case selection needs moving forward. See their figures on lesion treatment images and the map of accessible vs inaccessible lesions with the rigid device. With further refinement and study, this looks like a possible setup for in-office treatment of recurrent low-grade lesions. Retrospective Study Hamamoto et al2 studied a pathologic method of predicting recurrent urothelial upper tract disease outside the urinary tract. They described a histological finding of small cluster invasion as the concept of an extension of tumor budding at the invasive front of a lesion. With a cutoff defined, they analyzed small cluster invasion along with standard prognostic features, and found to be a predictor of extraurothelial recurrence and mortality in a multivariate analysis. The concept will need formal study and more validation on small cluster invasion grading but looks to be a promising direction in upper tract pathologic staging. Amason et al3 constructed a nomogram with application access to incorporate standard predictors of prostate cancer screening into a biopsy prediction—now including MRI findings. The model achieved an AUC of 82%, with 61% sensitivity, 82% specificity, and 74% overall accuracy. The significant predictors were prostate volume, PSA, PSA density, prostate imaging reporting and data standards score, and age. Obviously, this nomogram requires a practice pattern of prebiopsy MRI in the first place. The nomogram needs more non-White population validation and hopefully could include future versions that add secondary biomarkers, if available. Luca et al4 explored the debates around MRI fusion biopsy by adding a microultrasound analysis at the same setting and analyzing whether double-targeted biopsy cases have a significant miss rate if systematic cores were omitted. In a retrospective series of 155, only 1 patient with dual imaging region of interest had a grade group 2 or more on systematic biopsy. In groups where the MRI and microultrasound are not dual positive, then systematic biopsy remains significant. Other studies are pending with randomization that will shed additional light on whether microultrasound is an adjunct or replacement to MRI. Finally, Bushweller et al5 looked at the current AUA match process and asked program directors to complete surveys on the application process, now that board scoring is different. The surveys confirmed that the top 2 evaluation tools were the subinternship and the letters of recommendation. Overall, 9 evaluation areas were surveyed, and a scored step 2 board score helped also. As with most survey studies, response rates are often a limitation.
No takes yet. Share an insight, caveat, or question.
Zahalka et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: